{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-002398","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.289382+00:00","generated_at":"2026-06-20T19:34:12.625452+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CytomX inks $35M upfront deal with Moderna for mRNA-Probody therapies; milestones up to $1.2B","bullets":["Upfront payment of $35M includes $5M pre-paid research funding; potential milestones total $1.2B.","Tiered royalties on net sales from high single digit to low-teen percentages per licensed product.","Moderna gets exclusive worldwide license to CytomX Probody platform for mRNA-encoded conditionally-activated therapies.","Moderna has a one-time option to participate in a future CytomX equity financing.","Collaboration covers oncology and non-oncology programs; Moderna can terminate on product-by-product basis after 2 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-002398","json":"https://secwatch.observer/filing/0001193125-23-002398.json","markdown":"https://secwatch.observer/filing/0001193125-23-002398.md","text":"https://secwatch.observer/filing/0001193125-23-002398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312523002398/0001193125-23-002398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312523002398/d405031d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:34:12.625452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"154b9ab504a6b579057767b78d62653bf3eac68d","claim":"CytomX Therapeutics, Inc. entered into Collaboration and License Agreement with ModernaTX, Inc., a wholly-owned subsidiary of Moderna, Inc. valued at $35 million (effective 2022-12-30).","evidence_excerpt":"On December 30, 2022, CytomX Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration and License Agreement”) with ModernaTX, Inc., a wholly-owned subsidiary of Moderna, Inc. (“Moderna”),","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312523002398/0001193125-23-002398-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"ModernaTX, Inc., a wholly-owned subsidiary of Moderna, Inc."},{"label":"Value","value":"$35 million"},{"label":"Effective","value":"2022-12-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}